Back to Search Start Over

Preclinical protein signatures in blood predict Crohn's disease and Ulcerative colitis several years before the diagnosis

Authors :
Grännö, O.
Salomon, Benita
Lindqvist, C. M.
Hedin, C. R. H.
Carlson, M.
Dannenberg, Katharina
Andersson, Erik
Söderholm, J. D.
Keita, Å. V.
Öhman, L.
Magnusson, M. K.
D'Amato, M.
Eriksson, Carl
Hultdin, J.
Kruse, Robert
Cao, Yang
Repsilber, Dirk
Bergemalm, Daniel
Grip, O.
Karling, P.
Halfvarson, Jonas
Grännö, O.
Salomon, Benita
Lindqvist, C. M.
Hedin, C. R. H.
Carlson, M.
Dannenberg, Katharina
Andersson, Erik
Söderholm, J. D.
Keita, Å. V.
Öhman, L.
Magnusson, M. K.
D'Amato, M.
Eriksson, Carl
Hultdin, J.
Kruse, Robert
Cao, Yang
Repsilber, Dirk
Bergemalm, Daniel
Grip, O.
Karling, P.
Halfvarson, Jonas
Publication Year :
2024

Abstract

Background: We aimed to identify protein signatures predictive of a future diagnosis of inflammatory bowel disease (IBD). Methods: We conducted a case-control study, nested within large population-based cohorts with biorepositories. Samples were obtained from individuals who later in life were diagnosed with IBD (preclinical cases) and compared with age and sex-matched individuals who remained free from IBD during follow-up (controls). Using proximity extension assays (Olink, Uppsala), we measured 176 proteins. We applied regularized logistic regression to identify protein signatures of preclinical disease in serum from the discovery cohort (n=312). Their performance was validated in an external preclinical cohort (n=222). The biological relevance of identified proteins was further assessed in an inception cohort (n=144). Finally, we used an IBD twin cohort (n=327) to examine the impact of genetic and shared environmental factors on identified proteins. Results: We identified 34 proteins associated with preclinical Crohn’s disease (CD) in the discovery cohort (Pfalse discovery rate <0.10), with 9 confirmed in the validation cohort (Pfalse discovery rate <0.05). For preclinical ulcerative colitis (UC), 45 proteins were identified and 12 validated (Fig. 1A-B). In the discovery cohort, a signature of 29 proteins differentiated preclinical CD cases from controls with an AUC of 0.85 (Fig. 1G). Its performance was confirmed when applied to the preclinical validation cohort (AUC=0.84, Fig. 1H). Moreover, the signature had excellent capacity to differentiate newly diagnosed CD from healthy controls in the inception cohort (AUC = 0.99, Fig. 1I). The preclinical UC signature had a significant, but albeit lower, predictive capacity in the discovery (AUC=0.77), validation (AUC=0.67) and inception cohort (AUC=0.90, Fig. 1G-I).15 of 17 proteins associated with preclinical IBD demonstrated significantly higher intra-pair correlation coefficients in healthy monozygotic- compa

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1442943233
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1093.ecco-jcc.jjad212.0426